ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur ATOZET®:MSD Merck Sharp & Dohme AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
C10BA05 - Atorvastatin and EzetimibeATC-DDD Version 2016. Source: WHO
C - Cardiovascular System
 
C10 - Lipid Modifying Agents
 

The DDDs are based on the treatment of hypercholesterolemia.

C10B - Lipid Modifying Agents, Combinations

Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.

For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.

C10BA - Hmg Coa Reductase Inhibitors in Combination with Other Lipid Modifying Agents
 

The DDD for the fixed combination of simvastatin or atorvastatin and ezetimibe is 1 UD (1 tablet), regardless of strength.
The DDD for the fixed combination of pravastatin and fenofibrate is 1 UD (1 tablet), regardless of strength.

C10BA05 - Atorvastatin and Ezetimibe
2020 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home